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Aim. To develop the model system for processing bodies (PBs) state monitoring and accomplish it in the
future as a possible read-out of mTOR activity in mammalian cells. Methods. In course of this study we
raised polyclonal antibodies against one of the PBs scaffold proteins – RCD-8 and employed cell imaging
technique. Results. It has been shown that the obtained antibodies recognize the  intracellular structures,
namely PBs. The detected protein co-localized with known marker of PBs – DCP1a, and partly with marker
of SGs – CPEB. Conclusions. Based on changes of PBs number and size in cells after exposure to known
inductors or inhibitors of PB formation we prove the specificity of generated antibodies and possibility of
their application for studies on the processing bodies dynamics controlled by mTOR-dependent signaling. 
Key words: mRNA processing, decapping, processing bodies, immunocytochemistry.
Introduction. Nascent mRNA transcripts are modified 
co-transcriptionally at their 5' end with 7-methylgua-
nosine (m
7G) cap and 3' end by adding adenylic nuc-
leotides to form poly(A) tail [1]. The  cap structure is
absolutely necessary for accomplishment of mRNA
functions and is involved in RNA processing (through
activation of formation of poly(A) tail and promoting
pre-mRNA splicing), translation initiation, protection
of mRNA from  5' ﬁ 3' cleavage, etc. [2, 3]. There is
well known and studied interaction between the trans-
lation initiation components and cap itself during trans- 
lation. With no direct involvement in the cap metabo-
lism, these proteins protect the cap structure from de-
gradation sterically by preventing nucleases from ac-
cessing this region of mRNA. From the other hand, the
m
7G cap itself prevents exonucleolytic degradation of
mRNA; thus, its removal triggers  rapid and complete
degradation of mRNA. This process is known as de-
capping and it is irreversible in contrast to deadenyla-
tion [1, 4]. 
The precise mechanism of decapping control is un-
known, however, according to a proposed model the
decapping rate is controlled by a steric competition for
the cap structure between the decapping enzyme and
the translation initiation machinery. When the cap bin-
ding protein, eIF4E (eukaryotic translation initiation
factor 4E), is bound to the cap structure, mRNA de-
capping is blocked. Dissociation of eIF4E from the cap
structure is a key step in facilitating decapping [5]. The
formation of  translational initiation complex on the cap 
structure also depends on the phosphorylation status of
eIF4E binding proteins (4E-BPs) which bind to eIF4E
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￿  Institute of Molecular Biology and Genetics NAS of Ukraine, 2010 and prevent its association with eIF4G thereby inhi-
biting the cap-dependent translation of mRNA [6].
4E-BPs are well characterized downstream effec-
tors of PI3K/mTOR signaling pathway. It is known that 
the phosphorylation of S6Ks and 4E-BPs by mTOR
regulates the rate of translation initiation in response to
diverse extracellular stimuli, such as growth factors,
mitogenes and nutrients [5, 7]. 
The assembly of translationally active cap-binding
eIF4F complex is controlled by the state of 4E-BP1
phosphorylation mediated by the mTOR signaling
pathway. It is logical to speculate that formation of the
cap-dependent translation initiation complex may af-
fect the rate of mRNA translation through a block of de- 
capping of these matrices. PI3K/mTOR signaling path-
way may regulate mRNA translation through phospho-
rylation of 4E-BPs and in this way decrease decapping
activity (accordingly to a model of steric competition
for binding to the cap).  
In mammalian cells, a pool of nontranslating
mRNAs can be accumulate in two types of cytoplasmic
mRNP granules: processing bodies (PB), which gene-
rally contain the mRNA decay machinery and stress
granules (SG), which contain a set of proteins, involved 
in the translation initiation including 40S ribosomal
subunit [3]. The recent data suggest that PBs are invol-
ved in the cytoplasmic processing of mRNA and play a
critical role in mRNA degradation and post-transcrip-
tional gene silencing [8, 9]. 
One of the specific scaffold proteins of PBs is RCD- 
8 (also known as Ge-1, EDC-4). Using human sera
screening it was first identified as autoantigen [10–12].
In cells RCD-8 was shown to co-localize with previous- 
ly identified PB components, including proteins, invol-
ved in mRNA decapping (DCP1a and DCP2), and the
autoantigen GW182 [12]. An exact role of RCD-8 is
not clear yet, but there are several observations indi-
cating that RCD-8 might be a scaffold protein for the
decapping machinery and can promote the interaction
between hDCP1 and hDCP-2 [13]. Down regulation of
RCD-8 in the cell by siRNA-mediated knock-out pre-
vents DCP1a and DCP2 from accumulating in PBs and
affects mRNA degradation [12].
The aim of current work was to develop a model
system for PBs monitoring (possible changes in PBs
number and/or size) by employing cell imaging tech-
nique and conduct it in future as a possible read-out of
the mTOR/PI3K signaling activity in mammalian cells.
 Materials and Methods. Production and purifica- 
tion of fusion protein. cDNA of RCD-8 was kindly pro-
vided by Dr. Ivan Gout (UCL, UK). A cDNA fragment
corresponding to 1–150 aa of human RCD-8 was clo-
ned into pET24a vector in frame with the N-terminal 6-
His-GST tag («Novagen», USA). pET24a- His-RCD-8
was then transformed into BL21DE3 Escherichia coli
strain. The expression of recombinant proteins was
induced with 1 mM isopropyl-b-D-(2)-thiogalactopyra- 
noside (IPTG) for 5 h at 30 °C. Affinity purification of
recombinant His-RCD-8 from bacteria cell lysates was
carried out on Ni-NTA agarose («Qiagen», USA) ac-
cording to the manufacturer’s recommendations. The
purity of the fusion proteins was confirmed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE).
Plasmids and antibodies. Plasmids, encoding RFP-
DCP and GFP-CPEB were kindly provided by Dr.
Dominique Weil. Rabbit anti-RCD-8 antibodies were
obtained from Bethyl Laboratories. Anti-mouse FITC-
conjugated antibodies were from Jackson Immuno-
Research Laboratories. Anti-mouse Texas Red-conju-
gated antibodies were from «Invitrogen» (USA). Se-
condary HRP-labelled anti-mouse and anti-rabbit anti-
bodies were from «Cell Signaling» (USA). 
Cell culture and immunocytochemistry. HEK293
cells were obtained from the American Type Culture
Collection and maintained in DMEM supplemented
with 10 % fetal bovine serum («HyClone», UK), peni-
cillin (200 U/ml) and streptomycin (200 mg/ml). To in-
duce PBs assembly/disassembly HEK293 cells were
exposed to sodium arsenite (III) (0.5 mM) or puro-
mycin (25  mg/ml) or CHX (50 mg/ml) for 0.5 h at 37 
oC.
All reagents were obtained from «SIGMA» (USA). For
immunofluorescent staining HEK293 cells were grown
in tissue culture chambers («Nunc», Denmark), fixed
with 3.7 % paraformaldehyde in PBS, and permeabi-
lized with PBS-T (0.2 % Tween-20) three times for
5 min. Unspecific binding was blocked by 45 min
incubation of cells with  5 % FBS diluted in PBS-T.
Afterwards staining with primary and secondary
antisera was performed as described previously [11].
Transfections were carried out in 24 well plates using
2 µg of DNA and JetPEI reagent («PolyPlus», France)
513
NOVEL ANTIBODIES AGAINST RCD-8 AS A TOOL TO STUDY PROCESSING BODIESas manufacturer recommended. 24 hours after trans-
fection cells were fixed and stained with anti-RCD-8
antibodies. Fluorescently labelled cells were viewed
with a Zeiss LSM Meta 510 confocal microscope, and
the images were analyzed using the LSM510 image
browser software. 
SDS-PAGE, Western blotting. HEK293 or E. coli
cell protein extracts were resolved in SDS-polyacryl-
amide gels and transferred to PVDF membranes. Mem-
branes were incubated in blocking solution and probed
with rabbit anti-RCD-8 (1:5000) antibodies diluted in
25 mM Tris-HCl (pH 7.4), 0.8 % NaCl, 0.02 % KCl,
and 0.05 % Tween (TBST). Immune complexes were
detected using HRP-labelled anti-rabbit antibodies.
Immunoprecipitation. HEK293 cells were washed
twice with ice-cold PBS and then lysed using lysis buf-
fer EB (150 mM NaCl, 50 mM Tris, pH7.5, 0.5 mM
EDTA, 0.5 mM NaF, 0.5 % Triton X-100, Coctail of
protease inhibitors). After incubation for 30 min on ice
the lysate was centrifuged for 15 min at 13,000 · g. Su-
pernatant was incubated with anti RCD-8 antibodies
and protein A-sepharose («GE Healthcare», UK). Then
beads were washed four times with EB buffer. Next,
immunoprecipitates and total protein extracts were re-
solved by SDS-PAGE and transferred to PVDF mem-
branes («Millipore», USA). The membrane was blo-
cked with 5 % skim milk in TBST for 1 h, and then in-
cubated with anti-RCD-8  antibodies. After washing
three times with TBST the membrane was incubated
with HRP-conjugated goat anti-rabbit IgG («Prome-
ga», USA). Finally, the membrane was developed using 
an ECL kit («GE Healthcare») and then exposed to Ag-
fa X-ray film. Non-specific binding of RCD-8 to sepha- 
rose beads was analyzed in samples without  antibodies.
Results and Discussion. To generate anti-RCD8
antibodies a fragment of RCD-8 corresponding to 1–
150 aa was used as an antigen for mice immunization.
Recombinant His-RCD-8 was expressed in E. coli cells
and purified using Ni-NTA-agarose, as recommended
by the manufacturer. Using a standard scheme of im-
munization with boosting mice every 2 weeks, a titer of
nearly 105 of anti-RCD-8 antibodies in the serum of the 
immunized mice was achieved on the 45th day of im-
munization.
Polyclonal anti-RCD-8 antibodies were affinity pu- 
rified from polyclonal ascite fluid using antigen accor-
ding to the standard protocol [14]. The specificity of
purified antibodies was analyzed by immunoprecipita-
tion of endogenous RCD-8 from HEK293 cell lysate
(Fig. 1) and by Western blot analysis of HEK293 cell
lysate with overexpressed recombinant HA-tagged
RCD-8 (data not shown).
Next, we tested whether the obtained affinity pu-
rified anti-RCD-8 antibodies could detect RCD-8 in
PBs of mammalian cells. For this, we employed immu-
nofluorescense approach using different mammalian
cell lines (HEK293, MCF-7, HeLa, U2OS). We were
able to detect some discrete structures in all cell lines,
particularly in HEK293 (Fig. 2, see inset).  Number of
these structures varied depending on cells type (data not 
shown), which is in good agreement with previous ob-
servations [8–13, 15, 16]. To check whether these struc- 
tures are PBs we overexpressed the markers of PBs and
SGs fused with fluorescent proteins (DCP1- RFP- or
CPEB-GFP correspondently) in HEK293 cells. Using
confocal microscopy we were able to confirm co-
localization of DCP1-RFP with structures detected by
generated anti-RCD-8 antibodies. In this way we
confirmed the specificity of purified antibodies with
respect to PB (Fig. 3, see inset). Partial merge of signals 
obtained from anti-RCD-8 antibodies and CPEB-GFP
could be explained by physical association between
PBs and SGs, because CPEB is a known inductor of SG
in the cells [15, 16] (Fig. 4, see inset). 
According to the presented data, RCD-8 is locali-
zed only in PB but we can’t exclude the presence of
RCD-8 in other sites where its content is lower. 
Next we verified the specificity of anti-RCD-8 an-
tibodies using well known agents that promote assem-
bly/disassembly of PBs. According to the previously
published data the treatment of mammalian cells with
cycloheximide (which inhibits translation elongation
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Fig. 1. Immunoprecipitation of endogenous RCD-8 from HEK293
cell lysate. Supernatant was incubated with anti-RCD-8 antibodies
and protein A-sepharose. Immune complexes were analyzed by
immnunoblotting using anti-RCD-8 (Bethyl Laboratories) antibo-
dies. Non-specific binding of RCD-8 to sepharose beads was
analyzed in sample without  antibodiesFigures to article by D. O. Gudkova et al.
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Fig. 2. Processing bo-
dies in HEK293 cells.
Cells were fixed with
3.7 % FA and stained
with a-RCD-8 antibodi-
es (ab) ( a ). As secon-
dary FITC-conjugated
anti-mouse ab were
used. Nuclei ( b ) were
stained with Hoechst.
Picture  c represents a
merge of signals. · 100
c a b
b a c
Fig. 4. Discrete foci are
partly co-localized with
known marker of stress
granules – CPEB. HEK-
293 cells were transfec-
ted with CPEB-GFP (a).
In a day they were fixed
with 3.7 % FA and stai-
ned with a-RCD-8 anti-
bodies (ab) (b). As se-
condary Texas Red-con- 
jugated anti-mouse ab
were used. Picture c re-
presents a merge of sig-
nals. · 100
a b c d
Fig. 5. HEK293 cells were treated with sodium arsenite 0.5 mM (a), cycloheximide 50 mg/ml (b) and puromycin 25 mg/ml (c) during 30 min. Picture d
represents untreated cells. Then cells were fixed with 3.7 % FA and stained with a-RCD-8 antibodies (ab). As secodary FITC-conjugated anti-mouse 
ab were used. Nuclei were stained with Hoechst. · 100
c a b
Fig. 3. Discrete foci are
co-localized with known
marker of processing bo-
dies – DCP1a. HEK293
cells were transfected
with DCP- RFP (a). After
24 h cells were fixed with
3.7 % FA and stained with 
a-RCD-8 antibodies (ab)
(b). As secondary FITC-
conjugated anti-mouse ab
were used. Picture  c re-
presents a merge of sig-
nals. · 100and traps mRNAs on polysomes) decreases the flow of
mRNA to PBs and causes rapid loss of these foci [11].
Conversely, some drugs (e. g. puromycin) release
mRNA from ribosomes resulting in an increase of PBs
number and size and making mRNA available to
decapping machinery [3, 16]. Arsenite is also a known
inductor of PBs in mammalian cells [3, 11, 15, 16]. A
precise mechanism of this action is not clear yet, but
there are some lines of evidence indicating that arsenite
greatly decreases the level of gluthathione causing the
oxidative stress [17]. 
In our experiment we treated HEK293 cells with
inductors of PBs, such as puromycin (25 mg/ml) and
arsenite (0.5 mM), and inhibitor of PBs – cycloheximi-
de (50 mg/ml). After PBs induction or inhibition of PBs
assembly we fixed HEK293 cells and stained them with 
anti-RCD-8 antibodies. According to the data pre-
sented in Fig. 5 (see inset) treatment of cells with PB
inductors greatly increased the number and size of cell
structures recognized with anti-RCD-8 antibodies and
contrary, the treatment with inhibitor of PBs caused op- 
posite effect. These data provide an additional evidence 
of anti-RCD-8 antibodies specificity.
Conclusions. In this study we obtained polyclonal
antibodies that recognized RCD-8-component of PBs.
We verified their specificity by Western blot, immuno-
precipitation assay, and by immunofluorescence using
known marker of PBs and conditions that promote their
assembly/disassembly. In view of the absence of publi-
shed data regarding   regulation of PB dynamics by cell
signaling pathways these antibodies could be a great to- 
ol to study these processes. 
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Д. О. Гуд  ко  ва, Г. Г. Па  на  сюк, І. О. Не  ма  за  ний, В. В. Філо  нен  ко
Нові ан  титіла про  ти RCD-8 як інстру  мент для вив  чен  ня 
про  це  сив  них тілець 
Ре  зю  ме
Мета. Роз  ро  би  ти мо  дель  ну сис  те  му для вив  чен  ня ста  ну про  -
це  сив  них тілець як мож  ли  во  го по  каз  ни  ка ак  тив  ності mTOR-
кінази в кліти  нах ссавців. Ме  то  ди. Виділено полікло  нальні ан -
титіла до од  но  го з основ  них білків про  це  сив  них тілець – RCD-8
із за  сто  су  ван  ням ме  тоду іму  но  ци  тохімії. Ре  зуль  та  ти. По  ка -
за  но, що от  ри  мані ан  титіла розпізна  ють внутрішньоклітинні 
струк  ту  ри, над  алі іден  тифіко  вані як  про  це  сивні тільця. Білок, 
що де  тек  тується ан  титілами, ло  калізується раз  ом з відо  мим
мар  ке  ром про  це  сив  них тілець (DCP1a) та час  тко  во – з мар  ке  -
ром стре  со  вих гра  нул (CPEB). Вис  нов  ки. На основі даних щодо 
зміни розмірів і кількості про  це  сив  них тілець у відповідь на об  -
роб  ку клітин відо  ми  ми індук  то  ра  ми та інгібіто  ра  ми утво  рен  -
ня  про  це  сив  них  тілець  до  ве  де  но  спе  цифічність  за  зна  че  них
ан  титіл і підтвер  дже  но мож  ливість їхньо  го ви  ко  рис  тан  ня
для досліджен  ня ди  наміки утво  рен  ня про  це  сив  них тілець під
контро  лем mTOR-за  леж  но  го сиг  наль  но  го шля  ху.
Клю  чові сло  ва: про  це  синг мРНК, де  кепінг, про  це  сивні тіль-
ця, іму  но  ци  тохімія.
Д. О. Гуд  ко  ва, А. Г. Па  на  сюк, И. А. Не  ма  за  ный,  В. В. Фи  ло  нен  ко
Но  вые ан  ти  те  ла к RCD-8 как инстру  мент для из  уче  ния  
про  цес  сив  ных те  лец
Ре  зю  ме
Цель. Раз  ра  бо  тать мо  дель  ную сис  те  му для из  уче  ния со  сто  я  -
ния про  цес  сив  ных те  лец как воз  мож  но  го по  ка  за  те  ля ак  тив  -
нос  ти mTOR-ки  на  зы в клет  ках мле  ко  пи  та  ю  щих. Ме  то  ды. Вы-
де  ле  ны по  лик  ло  наль  ные ан  ти  те  ла к од  но  му из основ  ных бел  ков
про  цес  сив  ных те  лец – RCD-8 с при  ме  нением ме  тода им  му  но  ци  -
то  хи  мии. Ре  зуль  та  ты. По  ка  за  но, что по  лу  чен  ные ан  ти  те  ла
узна  ют внут  рик  ле  точ  ные струк  ту  ры, иден  ти  фи  ци  ро  ван  ные
далее как  про  цес  сив  ные тель  ца. Де  тек  ти  ру  е  мый бе  лок ло  ка  ли  -
зу  ет  ся  вмес  те  с  из  вес  тным  мар  ке  ром  про  цес  сив  ных  те  лец
(DCP1a) и час  тич  но – с мар  ке  ром стрес  со  вых гра  нул (CPEB).
Вы  во  ды. На осно  ва  нии дан  ных об из  ме  не  ни  ях ко  ли  чес  тва и раз  -
ме  ра про  цес  сив  ных те  лец в от  вет на об  ра  бот  ку кле  ток из-
вес  тны  ми ин  дук  то  ра  ми и ин  ги  би  то  ра  ми об  ра  зо  ва  ния про  цес  -
сив  ных те  лец про  де  мо  нстри  ро  ва  на спе  ци  фич  ность указанных
ан  ти  тел и под  твер  жде  на воз  мож  ность их ис  поль  зо  ва  ния для
из  уче  ния ди  на  ми  ки об  ра  зо  ва  ния про  цес  сив  ных те  лец под конт-
ро  лем mTOR-за  ви  си  мо  го сиг  наль  но  го пути.
Клю  че  вые сло  ва: про  цес  синг мРНК, де  кеп  пинг, про  цес  сив  -
ные тель  ца, им  му  но  ци  то  хи  мия.
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